James Orsborne
Stock Analyst at Stifel Nicolaus
(0.16)
# 4,542
Out of 4,651 analysts
54
Total ratings
35%
Success rate
-17.8%
Average return
Main Sectors:
Stocks Rated by James Orsborne
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: OXB Oxford Biomedica plc | Reiterated: Buy | 725p → 950p | 487p | +95.07% | 10 | Mar 11, 2026 | |
| LON: ONT Oxford Nanopore Technologies plc | Upgraded: Hold | 100p → 140p | 122p | +14.75% | 9 | Jan 8, 2026 | |
| AIM: STX Shield Therapeutics plc | Upgraded: Buy | 4p → 10p | 4p | +129.89% | 4 | Oct 6, 2025 | |
| AIM: FUM Futura Medical plc | Reiterated: Buy | 140p | 0.41p | n/a | 7 | Apr 15, 2025 | |
| AIM: NIOX NIOX Group Plc | Maintained: Buy | 77p | 68p | n/a | 6 | Apr 11, 2025 | |
| AIM: HVO hVIVO plc | Reiterated: Buy | 30p | 7p | n/a | 11 | Apr 10, 2025 | |
| LON: HLN Haleon plc | Maintained: Hold | 340p → 370p | 356p | n/a | 4 | Feb 25, 2025 | |
| EPA: VLA Valneva SE | Reiterated: Buy | €6.50 | €3.00 | n/a | 1 | Sep 25, 2024 | |
| AIM: SCLP Scancell Holdings plc | Rated: Buy | 30p | 10p | n/a | 2 | Sep 19, 2023 |
Oxford Biomedica plc
Mar 11, 2026
Reiterated: Buy
Price Target: 725p → 950p
Current: 487p
Upside: +95.07%
Oxford Nanopore Technologies plc
Jan 8, 2026
Upgraded: Hold
Price Target: 100p → 140p
Current: 122p
Upside: +14.75%
Shield Therapeutics plc
Oct 6, 2025
Upgraded: Buy
Price Target: 4p → 10p
Current: 4p
Upside: +129.89%
Futura Medical plc
Apr 15, 2025
Reiterated: Buy
Price Target: 140p
Current: 0.41p
Upside: n/a
NIOX Group Plc
Apr 11, 2025
Maintained: Buy
Price Target: 77p
Current: 68p
Upside: n/a
hVIVO plc
Apr 10, 2025
Reiterated: Buy
Price Target: 30p
Current: 7p
Upside: n/a
Haleon plc
Feb 25, 2025
Maintained: Hold
Price Target: 340p → 370p
Current: 356p
Upside: n/a
Valneva SE
Sep 25, 2024
Reiterated: Buy
Price Target: €6.50
Current: €3.00
Upside: n/a
Scancell Holdings plc
Sep 19, 2023
Rated: Buy
Price Target: 30p
Current: 10p
Upside: n/a